What is HC Wainwright’s Estimate for ATNM FY2026 Earnings?

Actinium Pharmaceuticals, Inc. (NYSE:ATNM) – Equities researchers at HC Wainwright decreased their FY2026 earnings per share estimates for shares of Actinium Pharmaceuticals in a research note issued to investors on Monday, April 28th. HC Wainwright analyst J. Pantginis now expects that the company will post earnings of ($0.91) per share for the year, down from their previous estimate of ($0.88). HC Wainwright has a “Buy” rating and a $4.00 price objective on the stock. The consensus estimate for Actinium Pharmaceuticals’ current full-year earnings is ($1.41) per share.

Separately, StockNews.com upgraded shares of Actinium Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, April 18th. Two analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. Based on data from MarketBeat, Actinium Pharmaceuticals has a consensus rating of “Moderate Buy” and an average price target of $4.00.

Actinium Pharmaceuticals Stock Up 4.0 %

NYSE ATNM opened at $1.55 on Thursday. The firm has a market capitalization of $48.35 million, a PE ratio of -1.12 and a beta of -0.27. The stock’s 50 day moving average is $1.32 and its 200 day moving average is $1.37. Actinium Pharmaceuticals has a twelve month low of $1.03 and a twelve month high of $10.24.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in ATNM. Geode Capital Management LLC increased its holdings in shares of Actinium Pharmaceuticals by 3.0% during the third quarter. Geode Capital Management LLC now owns 686,153 shares of the company’s stock valued at $1,290,000 after acquiring an additional 19,843 shares in the last quarter. Northern Trust Corp raised its holdings in Actinium Pharmaceuticals by 4.9% in the fourth quarter. Northern Trust Corp now owns 251,930 shares of the company’s stock worth $317,000 after buying an additional 11,812 shares during the last quarter. Los Angeles Capital Management LLC lifted its stake in shares of Actinium Pharmaceuticals by 25.0% in the fourth quarter. Los Angeles Capital Management LLC now owns 213,950 shares of the company’s stock worth $270,000 after buying an additional 42,770 shares in the last quarter. Renaissance Technologies LLC grew its holdings in shares of Actinium Pharmaceuticals by 49.9% during the fourth quarter. Renaissance Technologies LLC now owns 190,400 shares of the company’s stock valued at $240,000 after buying an additional 63,400 shares during the last quarter. Finally, Squarepoint Ops LLC increased its position in shares of Actinium Pharmaceuticals by 25.4% during the fourth quarter. Squarepoint Ops LLC now owns 183,262 shares of the company’s stock valued at $231,000 after acquiring an additional 37,159 shares in the last quarter. Hedge funds and other institutional investors own 27.50% of the company’s stock.

Actinium Pharmaceuticals Company Profile

Actinium Pharmaceuticals, Inc develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML).